Innate Pharma presents two posters on proprietary BTG-ADC technology at the world ADC Summit
Initiation of a Phase I clinical trial of lirilumab in combination with elotuzumab
Third data and safety monitoring board meeting for EffiKIR trial recommends continuation as planned
First half of 2014: broadened clinical portfolio and strengthened cash position
Innate Pharma appoints Pierre Dodion as Chief Medical Officer and member of the Executive committee
Orphan drug designation in the European Union for IPH4102
Completion of target enrollment in the phase II EffiKIR trial
Number of shares and voting rights of Innate Pharma as at June 30, 2014
Innate Pharma raises 50 million euros in a capital increase subscribed by specialist institutional investors
Innate pharma launches a capital increase to raise up to 15% of current capital
